QJM : monthly journal of the Association of Physicians
-
Review Case Reports
Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
Posterior reversible encephalopathy syndrome (PRES) is a potentially devastating complication of bevacizumab treatment. ⋯ PRES is a catastrophic neurological complication of bevacizumab treatment, which responds favorably to prompt bevacizumab withdrawal and blood pressure control.
-
The management of diabetes during terminal illness is complex, with lack of agreement and consensus among physicians and multidisciplinary teams. Despite the plethora of guidelines available for the management of diabetes, there exists no agreed, evidence-based strategy for managing diabetes during terminal illness and at the end of life. ⋯ Furthermore, controversy exists on the frequency of blood glucose monitoring, the optimum blood glucose range and how to achieve this. We review the factors influencing blood glucose during terminal illness and provide a suggested approach to managing patients with type 1 and type 2 diabetes during the early and late stages of terminal illness.